Investigation of Immune Disorders and Deficiencies
The immune system is an intricate system comprised of specialized cells, proteins, tissues and organs. Proper functioning is critical to the body's ability to defend itself against harmful pathogens. Immunological disorders and deficiencies are defects in the immune system that lead to abnormal immune responses. Abnormal immune responses could be derived from immune deficiencies, dysregulations or hypersensitivities.
The overall goal of this research study is to identify the mechanisms of primary immune deficiencies and immune disorders at the genetic, cellular and molecular level, using novel analytic techniques to be performed on immune cells derived from blood samples. The knowledge gained from the aims of this study could lead to better diagnostics and identify novel targets for therapeutic interventions.
Primary Immune Deficiencies
Common Variable Immune Deficiencies
|Study Design:||Observational Model: Case-Control
Time Perspective: Prospective
|Official Title:||Investigation of Molecular, Genetic and Cellular Mechanisms of Human Immune Disorders and Deficiencies|
- Genetic variants [ Time Frame: 10 years ]To elucidate genetic variants associated with various previously identified immune disorders to include but not limited to immune dysregulations, hypersensitivities, inflammatory conditions and deficiencies.
- Pathogenesis [ Time Frame: 10 years ]To further elucidate pathogenesis of previously discovered immune disorders or subjects with suspected allergic/immunological disorders using cell surface and intracellular staining techniques using flow cytometry.
Biospecimen Retention: Samples With DNA
|Study Start Date:||December 2012|
|Estimated Study Completion Date:||December 2018|
|Estimated Primary Completion Date:||December 2018 (Final data collection date for primary outcome measure)|
Immune deficiencies/Immune disorders
Patients with abnormal immune responses or potential primary immune deficiencies or immune disorders (allergies, autoimmune diseases) will be enrolled as the study group.
No prior immune abnormalities
Patients with no prior immune abnormalities will be enrolled as the control group.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01981785
|United States, Virginia|
|O&O Alpan LLC|
|Fairfax, Virginia, United States, 22030|
|Principal Investigator:||Oral Alpan, MD||O & O Alpan LLC|